Forecasts and valuation
Maintain BUY and $2.40 price target. We continue to like the risk/reward asymmetry associated with the stock, now without a funding overhang and multiple key de-risking value inflection points.
Recall, we reach our $2.40 price target on a risked basis, and assume a 25% probability of success (PoS) in RP11, 15% in ADOA, 10% in ADPKD (autosomal dominant polycystic kidney disease) and 5% in Phelan McDermid. On a fully de-risked basis, we see potential upside to $12/share.
Elyse Shapiro | Analyst | Canaccord Genuity (Australia) Ltd. | [email protected] | +61.3.8688.9136 Madeleine Williams | Analyst | Canaccord Genuity (Australia) Ltd. | [email protected] | +61.3.8688.9102
- Forums
- ASX - By Stock
- Cannacord research conclusion today
PYC
pyc therapeutics limited
Add to My Watchlist
6.43%
!
$1.33

Forecasts and valuationMaintain BUY and $2.40 price target. We...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
$1.33 |
Change
0.080(6.43%) |
Mkt cap ! $772.8M |
Open | High | Low | Value | Volume |
$1.27 | $1.35 | $1.21 | $763.8K | 595.4K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 97719 | $1.30 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.33 | 6599 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 97719 | 1.300 |
1 | 4027 | 1.240 |
1 | 40000 | 1.220 |
1 | 1000 | 1.200 |
2 | 10830 | 1.190 |
Price($) | Vol. | No. |
---|---|---|
1.325 | 6599 | 1 |
1.395 | 7168 | 1 |
1.400 | 18450 | 1 |
1.420 | 26097 | 2 |
1.430 | 13000 | 1 |
Last trade - 16.10pm 08/08/2025 (20 minute delay) ? |
Featured News
PYC (ASX) Chart |